Working... Menu

LANTUSTITR: Insulin Glargine in Type 2 Diabetes Mellitus

The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Read our disclaimer for details. Identifier: NCT00349986
Recruitment Status : Terminated (prematurely terminated due to loss of interest)
First Posted : July 10, 2006
Last Update Posted : December 7, 2009
Information provided by:

Brief Summary:

The rationale of the study is to determine:

  • the first dose and the titration of basal insulin
  • the exact daily time administration of basal insulin in poorly controlled type II diabetic patients.

Condition or disease Intervention/treatment Phase
Diabetes Mellitus, Type 2 Drug: Insuline glargine Phase 4

Layout table for study information
Study Type : Interventional  (Clinical Trial)
Actual Enrollment : 4 participants
Allocation: Randomized
Intervention Model: Parallel Assignment
Masking: None (Open Label)
Primary Purpose: Treatment
Official Title: The Determination of the First Dose and the Optimal Time of Administration of Insulin Glargine Combined With Oral Antidiabetic Drug in Poorly Controlled Type II Diabetic Patients
Study Start Date : September 2006
Actual Primary Completion Date : June 2007

Resource links provided by the National Library of Medicine

Primary Outcome Measures :
  1. HgbA1c measurement

Information from the National Library of Medicine

Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the contacts provided below. For general information, Learn About Clinical Studies.

Layout table for eligibility information
Ages Eligible for Study:   40 Years to 65 Years   (Adult, Older Adult)
Sexes Eligible for Study:   All
Accepts Healthy Volunteers:   No

Inclusion Criteria:

  • Type 2 Diabetes Mellitus
  • Insufficient combined oral antidiabetic treatment (biguanide + sulfonylurea)
  • BMI >25 kg/m2 , <30 kg/m2
  • HbA1c value >7.0%, <9.0% within one month

Exclusion Criteria:

  • Type 1 Diabetes Mellitus
  • Known malignancy
  • Drug or alcohol abuse
  • Severe liver disease
  • Renal failure (se Creatinine > 150 micro mol/l)

The above information is not intended to contain all considerations relevant to a patient's potential participation in a clinical trial.

Information from the National Library of Medicine

To learn more about this study, you or your doctor may contact the study research staff using the contact information provided by the sponsor.

Please refer to this study by its identifier (NCT number): NCT00349986

Layout table for location information
Budapest, Hungary
Sponsors and Collaborators
Layout table for investigator information
Study Director: László Erős, MD Sanofi

Layout table for additonal information
Responsible Party: Medical Affairs Study Director, Sanofi-aventis Identifier: NCT00349986     History of Changes
Other Study ID Numbers: HOE901_4059
First Posted: July 10, 2006    Key Record Dates
Last Update Posted: December 7, 2009
Last Verified: December 2009

Additional relevant MeSH terms:
Layout table for MeSH terms
Diabetes Mellitus
Diabetes Mellitus, Type 2
Glucose Metabolism Disorders
Metabolic Diseases
Endocrine System Diseases
Insulin Glargine
Hypoglycemic Agents
Physiological Effects of Drugs